Motion sickness treatment market size in 2026 is estimated at USD 691.26 million, growing from 2025 value of USD 670.61 million with 2031 projections showing USD 804.55 million, growing at 3.08% CAGR over 2026-2031. This report is Segmented by Treatment Type (Anticholinergics, First-Generation Antihistamines, and More), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and More), Dosage Form (Oral Tablets/Chews, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
The motion sickness treatment market size for neurokinin-1 antagonists is forecast to climb from USD 83.37 million in 2026 to USD 107.68 million by 2031. Wearable devices, while outside traditional drug categories, now sit within payer formularies for pregnant users and chemotherapy patients. As regulatory bodies tighten labels on anticholinergics, manufacturers pivot toward combination packs pairing low-dose antihistamines with ginger extracts to defend share.
Europe ranks second in the motion sickness treatment market, aided by harmonised EMA rules that validate botanical options and tighten synthetic drug labelling. Germany and the United Kingdom invest in digital therapeutics for post-stroke vestibular rehab, indirectly advancing consumer acceptance. Ferry routes across Scandinavia and the Mediterranean create predictable spikes in seasonal demand, prompting pharmacies at ports to expand inventories.
Asia-Pacific posts the fastest regional CAGR at 4.22%. Japan pioneers age-friendly melt-in-mouth films, and local manufacturers bundle them with train tickets during national holidays. Chinese firms develop Western-traditional hybrids, blending scopolamine derivatives with ginger to suit cultural preferences. Cruise growth from Singapore and Australia amplifies exposure. Rising disposable incomes and broader e-commerce logistics collectively enlarge the motion sickness treatment market in the region.
Global Motion Sickness Treatment Market Trends and Insights
Expansion of Global Passenger Mobility and Tourism
Asia-Pacific travel volumes surpassed pre-2019 levels in early 2025, driving sustained consumption of preventive therapies among cruise and automotive passengers. Japanese drug makers responded with rapid-dissolving tablets tailored for elderly tourists, acknowledging the rising average age of travelers. Cruises have enlarged on-board pharmacy inventories, treating motion discomfort as essential infrastructure rather than discretionary spending. Airlines now partner with manufacturers to include sample patches in amenity kits, reinforcing habitual use during long-haul flights. This structural linkage between travel recovery and the motion sickness treatment market underpins volume stability across seasons.Rising Consumer Awareness and Self-Medication Practices
Direct-to-consumer branding and social media outreach have normalised over-the-counter therapies. Dramamine’s 75th-anniversary campaign in 2024 celebrated the decline of airline emesis bags, embedding the brand in popular culture. Widespread travel blogs promote personalised dosing tips, and mobile apps recommend timing for tablet intake based on itinerary data. Pharmacies report higher basket values as shoppers add natural ginger chews alongside antihistamines. These behaviours align with broader self-care trends and accelerate unit sales in the motion sickness treatment industry.Adverse Side-Effects and Safety Concerns of Existing Pharmacological Agents
In June 2025 the FDA required augmented warnings on scopolamine patches after 13 severe hyperthermia cases, including one death. Hospital audits linked transdermal scopolamine to higher delirium and pneumonia rates among seniors. Prescribers now favour shorter-acting antihistamines for cruises and space tourism flights. Litigation risk has widened insurance premiums for cruise lines that distribute patches. This scrutiny suppresses volumes in the core anticholinergic segment of the motion sickness treatment market.Other drivers and restraints analyzed in the detailed report include:
- Technological Innovations in Drug Delivery and Wearable Therapeutics
- Proliferation of Virtual and Augmented Reality Applications
- Increasing Adoption of Low-Cost Traditional or Herbal Alternatives
Segment Analysis
Anticholinergics captured 46.24% of the motion sickness treatment market in 2025, anchored by scopolamine patches valued for 72-hour protection. Recent hyperthermia alerts, however, have dented demand among cruise operators and pediatricians. First-generation antihistamines maintain relevance through well-known brands, though daytime drowsiness prompts consumers to explore non-sedating variants. Neurokinin-1 receptor antagonists show the quickest rise, posting a 5.26% CAGR thanks to pipeline assets that modulate vestibular signalling rather than neurotransmitter suppression. Herbal remedies and neuromodulation devices gather momentum as consumers weigh efficacy alongside safety.The motion sickness treatment market size for neurokinin-1 antagonists is forecast to climb from USD 83.37 million in 2026 to USD 107.68 million by 2031. Wearable devices, while outside traditional drug categories, now sit within payer formularies for pregnant users and chemotherapy patients. As regulatory bodies tighten labels on anticholinergics, manufacturers pivot toward combination packs pairing low-dose antihistamines with ginger extracts to defend share.
Complete Report Scope:
- By Treatment Type
- Anticholinergics (Scopolamine, Etc.)
- First-Generation Antihistamines (Dimenhydrinate, Meclizine, Etc.)
- Second-Generation / Non-Sedating Antihistamines
- Neurokinin-1 Receptor Antagonists (Tradipitant, VLY-686)
- Herbal & Nutraceuticals (Ginger, Peppermint, Etc.)
- Neuromodulation & Wearable Devices
- By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Travel Retail (Airports, Cruise-Ships)
- Hypermarkets & Convenience Stores
- By Dosage Form
- Oral Tablets / Chews
- Transdermal Patches
- Nasal Sprays & Gels
- Injectables / Infusions
- Wearable Neuromodulation Devices
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America contributed 42.01% of global revenue in 2025, supported by premium pricing, active FDA pathways, and strong insurance coverage for prescription therapies. Device innovators leverage Silicon Valley capital to commercialise vestibular headsets, and U.S. cruise operators stock branded OTC packets in cabin minibars. Canada follows similar patterns, while Mexico’s coastal resorts drive OTC sales to tourists.Europe ranks second in the motion sickness treatment market, aided by harmonised EMA rules that validate botanical options and tighten synthetic drug labelling. Germany and the United Kingdom invest in digital therapeutics for post-stroke vestibular rehab, indirectly advancing consumer acceptance. Ferry routes across Scandinavia and the Mediterranean create predictable spikes in seasonal demand, prompting pharmacies at ports to expand inventories.
Asia-Pacific posts the fastest regional CAGR at 4.22%. Japan pioneers age-friendly melt-in-mouth films, and local manufacturers bundle them with train tickets during national holidays. Chinese firms develop Western-traditional hybrids, blending scopolamine derivatives with ginger to suit cultural preferences. Cruise growth from Singapore and Australia amplifies exposure. Rising disposable incomes and broader e-commerce logistics collectively enlarge the motion sickness treatment market in the region.
List of Companies Covered in this Report:
- Prestige Consumer Healthcare
- Perrigo Company
- GlaxoSmithKline
- Pfizer
- Baxter
- Johnson & Johnson (McNeil)
- DM Pharma
- Lupin
- Reliefband Technologies
- Wellspring Pharmaceutical Corp.
- Caleb Pharmaceuticals
- Myungmoon Pharm Co., Ltd.
- Vanda Pharmaceuticals
- Bausch + Lomb Corp.
- Sun Pharmaceuticals Industries
- Dr. Reddy’s Laboratories
- Abbott Laboratories
- Yunnan Baiyao Group Co., Ltd.
- Church & Dwight Co., Inc. (Gravol)
- CVS Health Corp.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Prestige Consumer Healthcare Inc.
- Perrigo Company Plc
- GlaxoSmithKline Plc
- Pfizer Inc.
- Baxter International Inc.
- Johnson & Johnson (McNeil)
- DM Pharma
- Lupin Limited
- Reliefband Technologies, Inc.
- Wellspring Pharmaceutical Corp.
- Caleb Pharmaceuticals Inc.
- Myungmoon Pharm Co., Ltd.
- Vanda Pharmaceuticals Inc.
- Bausch + Lomb Corp.
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Abbott Laboratories
- Yunnan Baiyao Group Co., Ltd.
- Church & Dwight Co., Inc. (Gravol)
- CVS Health Corp.
